Mylan struck by disappointing financial results for 2018

27 February 2019
mylan_big

Shares in the Netherlands-incorporated generics drugmaker Mylan (Nasdaq: MYL) have suffered a near-10% hit in pre-market trading, following a disappointing financial results statement covering the final three months of 2018.

Total revenues were $3 billion, down 5% compared to the prior year period, with total revenues for 2018 coming in at $11 billion, down 4%.

Following Generally Accepted Accounting Principles (GAAP), the earnings per share (EPS) figure was $0.10, down 78%. For the full year, the EPS figure was $0.68, down 47%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics